Original Articles
  • Bohn RL, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol 2018 Mar-Apr;36(2):263-274.
  • Bykov K, Bohn R, Ewenstein BM, et al. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors. Thromb Haemost 2017;117(12): 2267-2273.
  • Gagne JJ, Rassen JA, Choudry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Drug Saf 2014;37(3):151-161.
  • Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc 2013;2(4):e000208.
  • Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21(12):1350-1358.
  • Feldman BM, Berger K, Bohn RL, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan AR, Schramm W. Haemophilia prophylazis: how can we justify the costs? Haemophilia 2012;18(5):1-5.
  • Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepid Drug Saf 2012;21 (8):810-817.

  • Eisenberg DF, Daniel GW, Jones JK, Goehring EL, Wahl PM, Winters P, Levin J, Bohn RL. Validation of a claims-based diagnostic code for Stevens-Johnson Syndrome in a commercially-insured population. Pharmacoepidem Drug Saf 2012; 21(7):760-764.

  • Wahl PM, Bohn RL, Terrell DR, George JN, Ewenstein B. Healthcare utilization of patients diagnosed with idiopathic thrombotic thrombocytopennic purpura in a commercially-insured population in the US. Transfusion 2012; 52:1614-1621.
  • Reis BY, Olson KL, Tian L, Bohn RL, Brownstein JS, Park PJ, Cziraky MJ, Wilson MD, Mandl KD. A Pharmacoepidemiologic network model for drug safety surveillance: Statins and rhabdomyolysis Drug Saf 2012; 35(3):395-406.
  • Wahl PM, Schneeweiss S, Wasser T, Rodgers JK, Daniel GW, Wilson M, Gagne JJ, Rasen JA, Patrick AM, Avorn J, Bohn RL. Early steps in development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf 2011; 35(5)407-416.
  • Wertz DA, Pollack M, Rodgers K, Bohn, RL, Sacco P, Sullivan S. Impact of Asthma Control on Sleep, Attendance at Work, Normal Activities and Disease Burden. Annals Allergy, Asthma & Immunol 2010; 105(2):118-123.
  • Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of Cardiovascular Events and All-cause Mortality in Patients Treated with Thiazolidinediones in a Managed Care Population. Circ Cardiovas Qual Outcomes 2010; 3:538-545.
  • Wahl PM, Terrell DR, George JN, Rodgers JK, Uhl L, Cataland S, Bohn RL. Validation of claims- based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. Thrombosis and Haemostasis 2010;103(6):1203-1209.
  • Wahl PM, Rodgers K, Schneeweiss S, Gage B, Butler J, Wilmer C, Nash M, Esper G, Gitlin N, Ostoborn N, Short LJ, Bohn RL. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmaceopidemiol Drug Saf 2010;19(6):596-603.
  • Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401-9.
  • Velentgas P, Bohn RL, Brown JS, Chan KA, Gladowski P, Holick CN, Kramer JM, Nakasato C, Spettell CM, Walker AM, Zhang F, Platt R. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf 2008;17(12):1226-1234.
  • Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepidemiol Drug Saf 2006;15(1):47-56.
  • Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005;11(3):261-269.
  • Walker AM, Bohn RL, Cali C, Cook SF, Ajene AN, Sands BE. Risk factors for colon ischemia. Am J Gastroenerol 2004;99(7):1333-13337.
  • Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004;10:63-68.
  • Solomon DH, Glynn RJ, Bohn RL, Levin R, Avorn J. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003;30(4):792-798.
  • Solomon DH, Katz JN, Carrino JA, Schaffer JL, Bohn RL, Mogun H, Avorn. Trends in Knee Magnetic Resonance Imaging. Med Care 2003;41(5):687-692.
  • Wang PS, Bohn RL, Knigh E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive sypmtoms and psychosocial factors. J Gen Intern Med 2002;17(7):504-511.
  • Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002;55(7):711-716.40.
  • Avorn J, Bohn RL, Levy E, Levin R, Owen W. Winkelmayer WC, Glynn RJ. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002;162(17):2002-2006.

  • Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. J Gen Intern Med 2002;15: 776-781.
  • Harding GF. Spencer EL. Wild JM. Conway M. Bohn RL. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 2002;58(8):1261-5.
  • Wang PS, Bohn RL, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatrics Soc 2001;49(12):1658-1690.
  • Harding GF. Spencer EL. Wild JM. Conway M. Bohn RL. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 2002;58(8):1261-5.
  • Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. American Journal of Psychiatry 2001;58(6):892-898.
  • Knight E, Bohn R, Wang P, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001;38:809-814.
  • Bohn RL. The economics of bleeding disorders. Haemophilia 2000;6(5):491-493
  • Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. J Gen Intern Med 2000; 15:776-781.
  • Colowick AB, Bohn RL, Avorn J, Ewenstein B. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 2000;96:1698-702.
  • Bohn RL, Gurwitz JH, Yeomans SM, Glynn RJ, Pasquale LR, Walker AM, Avorn J. Which patients are treated for glaucoma? An observational analysis. J Glauc 2000; 9:38-44.
  • Solomon DH, Katz JN, Bohn RL, Mogun H, Avorn J. Nonocccpational risk factors for carpal tunnel syndrome. J Gen Intern Med 1999;14(5):310-314.
  • Aledort LM, Miners A, Bohn RL, Borrero P, Goudemand J, Hoots K, Kavakli K, Lee C, Roberts J, Roberts J, Schramm W, Szucs T, Wasserman J. Economic aspects of haemophilia care. Haemophilia 1999;5(3):216-219.
  • Bohn RL, Colowick AB, Avorn J. Probabilities, costs, and outcomes: methodologic issues in modeling hemophilia treatment. Haemophilia 1999;5:374-378.
  • Bohn RL, Avorn J, Glynn RJ, Levin R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998;79:932-937.
  • Avorn J, Monette J, Mogun H, Bohn RL, Avorn J. Persistence of use of lipid-lowering medications. JAMA 1998;279:1458-1462.
  • Solomon DH, Katz JN, Bohn RL, Mogun H, Avorn J. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epi 1997;50:953-959.
  • Harari D, Gurwitz JH, Avorn J, Bohn RL, Minaker KL. How do older persons define constipation? Implications for therapeutic management. J Ger Int Med 1997;12(1):63-66.
  • Gurwitz JH, Bohn RL, Glynn RJ, Avorn J. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epi 1997;50:953-959.
  • Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 1996;86:1805-1808.
  • Monette J, Mogun H. Bohn RL, Avorn J. Concurrent use of antiulcerative agents. J Clin Gastroent 1997;24:207-213.
  • Monane M, Gurwitz JH, Bohn RL, Glynn RJ, Levin R, Monette J, Avorn J. The impact of thiazide diuretics on the initiation of lipid lowering therapy in the elderly. J Am Geriatr Soc 1997;45:71-75.
  • Harari D, Gurwitz JH, Bohn R, Minaker KL. Bowel habit in relation to age and gender: findings from the National Health Interview Survey and clinical implications. Arch Intern Med 1996;156:315-320.
  • Kalish SC, Bohn RL, Avorn J. Policy analysis of the conversion of histamine2 antagonists to over-the- counter use. Med Care 1997;35:32-48.
  • Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 1996;86:1805-1808.
  • Monane M, Gurwitz JH, Bohn R, Avorn J. Trends in medication choices for hypertension in the elderly: the decline of the thiazides. Hypertension 1995;25:1045-1051.
  • Avorn J, Bohn RL, Mogun H, Monane M, Walker AM. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274(22):1780-1782.
  • Monane M, Glynn RJ, Gurwitz JH, Avorn J. Trends in medication choices for hypertension in the elderly: the decline of the thiazides. Hypertension 1995;25:1045-1051.
  • Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker AM. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274(22):1780-1782.
  • Kalish SC, Bohn RL, Mogun H, Glynn RJ, Gurwitz JH, Avorn J. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Geriat Soc 1995; 43:967-973.
  • Bohn RL, Glynn RJ, Gurwitz JH, Everitt DE, Gilden D, Avorn J. Patterns of glaucoma medication use in the elderly 1980-1990. J Glaucoma 1994;3:259-264.10.
  • Ross-Degnan D, Soumerai S, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Intl. J. of Technology Assessment in Health Care 1995;11:327-344.
  • Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Choodnovskiy I, Avorn J. Topical glaucoma medications and cardiovascular risk in the elderly. Clin Pharmacol Ther 1994;55:76-83.
  • Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
  • Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272(10):781-786.
  • Monane M, Bohn RL, Gurwitz JH, Glynn R, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994;154:433-437.
  • Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Choodnovskiy I, Avorn J. Old age and race as determinants of initiation of glaucoma therapy. Am J Epidemiol 1993;138:395-406.
  • Avorn J, Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Gilden D, Everitt DE, Choodnovskiy I. Adverse pulmonary effects of topical beta-blockers used in the treatment of glaucoma. J Glaucoma 1993;2:158- 165.
  • Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and initiation of treatment for diabetes mellitus. Ann Intern Med 1993;118:273-278.

Book Chapters
  • Ewenstein BM, Putnam KG, Bohn RL. Nonhemophilic inhibitors of coagulation. In Kitchens CS, Alving BM, Kessler CM, eds. Consultive Hemostasis and Thrombosis. Philadelphia: WB Saunders Co. 2002;75-90.

Other Publications
  • Flamm CR, Mark D, Lefevre F, Bohn RL, Finkelstein B, Aronson N. Endoscopic Retrograde Cholangiopancreatography (ERCP). Evidence Report/Technology Assessment No. 50 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center under Contract No. 290-97- 0015). AHRQ Publication No. 02-E017. Rockville (MD): Agency for Healthcare Research and Quality. June 2002.

  • Flamm CR, Aronson N, Bohn R, et al. Use of Epoetin for Anemia in Chronic Renal Failure. Evidence Report/Technology Assessment No. 29 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center under Contract No. 290-97-0015). AHRQ publication No. 01- E016. Rockville (MD) Agency for Healthcare Research and Quality. August 2001.
  • Bendixen LM, Bohn RL, Croce P, Young SG. Risk communication effectiveness: a study of industry and community perceptions. Spectrum, August 1989.

Proceedings of Meetings
  • Brown SA, Aledort LM and the Round Table Group. Meeting Report. Economic Challenges in Haemophilia. Haemophilia 2005;11(1):64-72.

  • Bohn RL, Schramm W, Bullinger M, Van Den Berg M, Blanchette V. Meeting Report. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004;10(Suppl 1):2-8.
  • Aledort LM, Bohn RL, Bolton-Maggs P, et al. Meeting Report. Proceedings of conference held in London, 12-13 January 1998, to discuss bleeding disorders in women. Haemophilia 1998;4:145-154.

Thesis
  • Bohn RL. The diagnosis and management of primary open-angle glaucoma [dissertation]. Boston, MA: Harvard School of Public Health; 1998.

Abstracts & Presentations
  • Bohn RL, Cooney M, Deodhar A, Curtis JR, Golembesky A. A Systematic Review of Population-Based Incidence and Prevalence Estimates of Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. Pharmacoepidem Drug Saf 2016;25(Suppl. 3):118.

  • Bykov K, Bohn RL, Ewenstein BM, Avorn J, Seeger JD. Bypassing agents and the risk of thromboembolic events in patients with hemophilia and inhibitors. Pharmacoepidem Drug Saf 2014:23(S1):468.
  • Bykov K, Bohn RL, Ewenstein BM, Avorn J, Seeger JD. Use of Medicaid analytic extract for evaluation of drug use and health service utilization in patients with hemophilia. Value in Health 2012;15(4):A110- A111.
  • Bykov K, Bohn RL, Ewenstein BM, Avorn J, Seeger JD. Identification of hemophilia patients in Medicaid claims data. Pharmacoepidem Drug Saf 2012;21(S1):109.
  • Mehta V, Loscale RJ, Reynolds MW, Bohn RL, Trifiro G, Mark TL. Guidance regarding the identification, development, validation and translation of coding algorithms in Electronic Healthcare (EH) databases. Pharmacoepidem and Drug Saf 2010;19:s17-s18.
  • Eisenberg DF, Daniel GW, Subramanian U, Breen T, Bohn RL, Wahl PM, Heman WH. Validation of claims-based diagnostic codes for severe hypoglycemic events (SHEs) in a commercially insured population. Pharmacoepidem and Drug Saf 2010;19:s74.
  • Roseman MB, Wahl PM, Daniel G, Overhage JM, McGuire P, Thompson D, Rodgers K, Short L, Bohn RL, Tierney WM. Sensitivity and specificity of acute renal failure medical claims validated against electronic medical records. Pharmacoepidemiol and Drug Saf 2009;18:s20.
  • Bohn RL, Schramm W, Bullinger M, van den Berg M, Blanchette V. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004;10(Suppl 1):2-8.
  • Aronson N, Flamm CR, Bohn RL, Mark DH, Speroff T. Evidence-based assessment: Patient, procedure, or operator factors associated with ERCP complications. Gastrointest Endosc 2002 Dec;56(6 Suppl 2); S294-S302.
  • Ewenstein BM, Avorn J, Putnam KG, Bohn RL. Porcine factor VIII: Pharmacoeconomics of inhibitor therapy. Haemophilia 2002;8(Suppl 1):13-16.
  • Bohn RL, Kuntz K, Pasquale L, Walker A, Glynn RJ, Gurwitz J, Avorn A. A cost analysis of drugs vs. laser surgery to treat glaucoma. Pharmacoepidemiology and Drug Saf 1998;7(2):S86.
  • Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coagul Fibrinolysis 1996;7 Suppl 1:S35-S37.
  • Bohn RL, Avorn J. Reimbursement for hemophilia care in the United States: Current policies and future considerations. Seminars in Hematology 1994;31(2)Suppl 2:26-28.
  • Bohn RL, Avorn J. Cost-effectiveness: can it be measured? Seminars in Hematology 1993;30 (3) Suppl 2:20-23.
  • Barbone F, Bohn RL, O'Leary CC, Young SG. Use of attributable fractions in hearing loss compensation cases. Presented at the American Industrial Hygiene Conference and Exposition. Salt Lake City, UT, May 1991.

Correspondence
  • Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Heart failure and noncompliance in the elderly. Arch Int Med 1994;154:2109-10.

Contact

Are you an organization, academic group or potential client interested in working with Bohn Epidemiology? Contact Dr. Bohn directly at:

Hours
  1. Monday
    9:00am
    10:00pm
  2. Tuesday
    9:00am
    10:00pm
  3. Wednesday
    9:00am
    10:00pm
  4. Thursday
    9:00am
    10:00pm
  5. Friday
    9:00am
    10:00pm
  6. Saturday
    9:00am
    6:00pm
  7. Sunday
    9:00am
    12:00pm
Copyright Rhonda L. Bohn, LLC 2016 - Web Design by B12